We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate.
- Authors
Tan, C. C.; Harden, P. N.; Rodger, R. S. C.; Rowe, P. A.; Spooner, R. J.; Junor, B. J. R.; Briggs, J. D.
- Abstract
Background In a previous controlled study we showed that ranitidine significantly reduced the phosphate binding of aluminium hydroxide in patients with renal failure, probably by increasing intragastric pH. Methods In this study we have investigated the effect of ranitidine on the phosphate binding of calcium carbonate in fifteen dialysis patients. Ranitidine 300 mg or a placebo tablet was taken before breakfast for two 4-week periods in a double-blind crossover trial with no washout period. The mean daily dose of calcium carbonate was 2 g and neither the dose nor the patient's diet was changed during the study period. Blood was taken at 2-weekly intervals for serum phosphate, calcium, albumin, and alkaline phosphatase measurements, and at the end of each treatment period for parathyroid hormone (PTH) level. Results Serum phosphate concentrations were significantly higher during the ranitidine than the placebo phase, 1.78 (±0.43 SD) versus 1.59 (±0.49 SD) mmol/1 (P<0.001). Serum calcium, albumin, PTH, and alkaline phosphatase concentrations did not differ between the two treatment periods. Conclusion This study shows that ranitidine has a significant adverse effect on the phosphate binding of calcium carbonate in patients with renal failure.
- Publication
Nephrology Dialysis Transplantation, 1996, Vol 11, Issue 5, p851
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/oxfordjournals.ndt.a027412